The Neuromarker S-100B in Patients With Different Types of Intracranial Injury
1 other identifier
observational
1,800
1 country
1
Brief Summary
Abstract: The most widely studied neuro-markers in traumatic brain injury (TBI) are S100B and neurone specific enolase (NSE). S-100B is localized in astroglia. This marker is used to predict neuronal damage caused by traumatic brain injury. The investigators conduct a study to derive and validate the measurement of S-100B in serum of patients with different types traumatic brain injuries.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2012
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2012
CompletedFirst Submitted
Initial submission to the registry
May 30, 2012
CompletedFirst Posted
Study publicly available on registry
June 14, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2013
CompletedNovember 21, 2013
November 1, 2013
1.5 years
May 30, 2012
November 20, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
S100B LEVEL
S-100B level higher than 0.105 ug/L is held pathological
14 month
Study Arms (6)
Epidural H.
patients with hematoma epidurale
Subdural H.
patients with hematoma subdurale
Subarachnoidal H.
patients with hematoma subarachnoidale
Intracerebral H.
patients with hematoma intracerebrale
E. cerebri
patients with edema cerebri
Concussion
patients with concussion
Eligibility Criteria
Patients from Level 1 trauma center
You may qualify if:
- all patients with traumatic brain injury
You may not qualify if:
- patients without traumatic brain injury
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Medical University of Vienna
Vienna, Vienna, A-1090, Austria
Related Publications (3)
Unden J, Bellner J, Astrand R, Romner B. Serum S100B levels in patients with epidural haematomas. Br J Neurosurg. 2005 Feb;19(1):43-5. doi: 10.1080/02688690500089381.
PMID: 16147582BACKGROUNDBiberthaler P, Linsenmeier U, Pfeifer KJ, Kroetz M, Mussack T, Kanz KG, Hoecherl EF, Jonas F, Marzi I, Leucht P, Jochum M, Mutschler W. Serum S-100B concentration provides additional information fot the indication of computed tomography in patients after minor head injury: a prospective multicenter study. Shock. 2006 May;25(5):446-53. doi: 10.1097/01.shk.0000209534.61058.35.
PMID: 16680008BACKGROUNDMussack T, Kirchhoff C, Buhmann S, Biberthaler P, Ladurner R, Gippner-Steppert C, Mutschler W, Jochum M. Significance of Elecsys S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients. Clin Chem Lab Med. 2006;44(9):1140-5. doi: 10.1515/CCLM.2006.190.
PMID: 16958611BACKGROUND
Biospecimen
7ml of blood drawed from peripheral vein
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Harald Wolf, M.D.
Dept. Trauma Surgery; Medical Univ. of Vienna, Austria
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
May 30, 2012
First Posted
June 14, 2012
Study Start
May 1, 2012
Primary Completion
November 1, 2013
Study Completion
November 1, 2013
Last Updated
November 21, 2013
Record last verified: 2013-11